Arcutis Biotherapeutics Inc (ARQT) is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. The company's pipeline includes topical and oral therapies for a range of dermatological conditions, including psoriasis, atopic dermatitis, seborrheic dermatitis, and vitiligo.
Arcutis' lead product candidate is ARQ-151, a topical cream for the treatment of plaque psoriasis. The company also has several other product candidates in development, including ARQ-154, a topical foam for the treatment of seborrheic dermatitis, and ARQ-252, an oral medication for the treatment of atopic dermatitis.
Arcutis was founded in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics Inc (ARQT) is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. The company's pipeline includes topical and oral therapies for a range of dermatological conditions, including psoriasis, atopic dermatitis, seborrheic dermatitis, and vitiligo.